Trial Profile
An Exploratory, Open-Label Phase I Pharmacodynamic Study of COX-2 Inhibition With Celecoxib (Celebrex) and Aromatase Activity in Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary)
- Indications Breast cancer; Ductal carcinoma
- Focus Therapeutic Use
- 12 Jun 2010 Results presented at ASCO 2010.
- 30 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.